SCHEMBL1153589

SCHEMBL1153589

Cc1ccc(C(O)(c2ccc(C)cc2)[C@@H](CC(C)C)NC(=O)C2(C(=O)N[C@H](CC(C)C)C(O)(c3ccc(C)cc3)c3ccc(C)cc3)CCCC2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 1/20 0.39
PSMB11 A5LHX3 2/20 0.36
PSMA7 O14818 2/20 0.36
PSMB1 P20618 2/20 0.36
PSMA1 P25786 2/20 0.36
PSMA2 P25787 2/20 0.36
PSMA3 P25788 2/20 0.36
PSMA4 P25789 2/20 0.36
PSMB8 P28062 2/20 0.36
PSMB9 P28065 2/20 0.36
PSMA5 P28066 2/20 0.36
PSMB4 P28070 2/20 0.36
PSMB6 P28072 2/20 0.36
PSMB5 P28074 2/20 0.36
PSMB10 P40306 2/20 0.36
PSMB3 P49720 2/20 0.36
PSMB2 P49721 2/20 0.36
PSMA6 P60900 2/20 0.36
PSMA8 Q8TAA3 2/20 0.36
PSMB7 Q99436 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1152996 0.99 ANPEP (0.38) ANPEPPSMB11PSMA7PSMB1PSMA1
SCHEMBL1153012 0.97 ANPEP (0.39) ANPEPPSMB11PSMA7PSMB1PSMA1
SCHEMBL1153986 0.95 ANPEP (0.40) ANPEPPSMB11PSMA7PSMB1PSMA1
SCHEMBL1153629 0.88 CTSL (0.40) ANPEPPSEN1PSEN2APH1BNCSTN
SCHEMBL1152940 0.87 CTSL (0.39) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1154111 0.86 ANPEP (0.42) ANPEPMEN1KMT2AMAPTALDH1A1
SCHEMBL1152498 0.86 PSEN1 (0.41) ANPEPPSEN1PSEN2APH1BNCSTN
SCHEMBL1153206 0.85 ANPEP (0.41) ANPEPSLC6A4SLC6A3MEN1KMT2A
SCHEMBL1153265 0.84 ANPEP (0.42) ANPEPMEN1KMT2AALDH1A1TDP1
SCHEMBL1153031 0.84 KEAP1 (0.35) KEAP1NFE2L2HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943799-B2 Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-17 US disclosed
US-20110046415-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENEBISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-02-24 US disclosed
US-7842839-B2 Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-11-30 US disclosed
US-20070112201-A1 Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-05-17 US disclosed
EP-1698617-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENE BISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF Sumitomo Chemical Company, Limited (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112201-A1 Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof CYP3A7, GRK7, CYP2A7 ANPEP 2755/4885PSMB11 3433/4885PSMA7 1153/4885
US-20110046415-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENEBISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF CYP3A7, GRK7, CYP2A7 ANPEP 2755/4885PSMB11 3433/4885PSMA7 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.